All sizes of pharmaceutical firms from giants like Johnson & Johnson to young guns like Moderna, yet to bring their first product to market, are vying to be the first to offer a vaccine for COVID-19. US regulators have already pulled back certain restrictions and requirements to bolster their efforts and move timetables forward. While some may see this as a good sign, 12 to 18 months is far from standard for vaccine development, a process usually discussed in terms of years. Similar urgency has proven reckless in the past and investors should approach this opportunity with caution.
To read this Market Insight, you’ll need to sign in
If you don’t have a subscription, sign up or start a free trial .
